Functional drug carriers formed by RGD-modified β-CD-HPG for the delivery of docetaxel for targeted inhibition of nasopharyngeal carcinoma cells.
Lingling XuChuan ZhouFan WangHuiqin LiuGuangyuan DongSiyi ZhangTao LiuPublished in: RSC advances (2022)
In this study, a drug delivery system was prepared by grafting the targeting molecule arginine-glycine-aspartic acid (RGD) onto hyperbranched polyglycerol (HPG)-modified β-cyclodextrin (β-CD-HPG) for the targeted inhibition of nasopharyngeal carcinoma (NPC) cells. The obtained β-CD-HPG-RGD with a relatively small size and low surface charge delivered docetaxel (Doc) effectively and displayed a targeting effect to human NPC HNE-1 cells, as confirmed by confocal laser scanning microscopy and flow cytometry. The in vitro drug release analysis exhibited the controlled drug release kinetics of the β-CD-HPG-RGD/Doc nanomedicine. β-CD-HPG-RGD/Doc effectively inhibited the proliferation of HNE-1 cells and promoted apoptosis. Moreover, its biocompatibility in vitro and in vivo was assessed. The results indicate that the β-CD-HPG-RGD/Doc nanomedicine has potential application in NPC targeting therapy.
Keyphrases
- drug release
- cancer therapy
- cell cycle arrest
- induced apoptosis
- drug delivery
- nk cells
- flow cytometry
- endoplasmic reticulum stress
- cell death
- endothelial cells
- oxidative stress
- nitric oxide
- squamous cell carcinoma
- emergency department
- locally advanced
- pi k akt
- climate change
- mass spectrometry
- bone marrow
- high speed
- smoking cessation
- capillary electrophoresis
- respiratory tract